National Hospital Organization Hanamaki Hospital

Recent papers from National Hospital Organization Hanamaki Hospital

1. Long-term safety, tolerability, and efficacy of subcutaneous efgartigimod PH20 in generalized myasthenia gravis: final results from a phase 3 open-label extension study (ADAPT-SC+)Frontiers in Neurology · 2026
2. Management of Exacerbations and Rescue TherapyJAMA Neurology · 2026
3. Comprehensive Care Goals in Myasthenia GravisNeurology Clinical Practice · 2026
4. Treatment Goals in Myasthenia Gravis: Expert Consensus Recommendations Using the RAND/UCLA Appropriateness Method (P4-9.004)Neurology · 2026
5. Long-term Safety and Efficacy of Subcutaneous Efgartigimod PH20 in Adult Participants With Generalized Myasthenia Gravis: Final Results of the ADAPT-SC+ Study (P9-9.002)Neurology · 2026
6. Myasthenia Gravis Inebilizumab Trial (MINT): Efficacy, Pharmacodynamics, and Immunogenicity in AChR+ Cohort (Week 52) (S14.009)Neurology · 2026
7. Associations between Neonatal Auditory Brainstem Response and Long-Term Language Development in Preterm ChildrenAmerican Journal of Perinatology · 2026
8. Long-term use of rozanolixizumab in generalised myasthenia gravis: final pooled analysis of the phase III MycarinG study and two open-label extensionsTherapeutic Advances in Neurological Disorders · 2026
9. Effect of Proteases in Fraction in Commercial Shio‐Koji on the Proteolysis of Bovine MyofibrilsAnimal Science Journal · 2026
10. Extrathymic malignancies in patients with myasthenia gravis: A Japanese multicenter studyInternal Medicine · 2026
11. Efficacy and safety of rozanolixizumab treatment cycles in patients with generalized myasthenia gravis: Final pooled analysis of Phase 3 studiesJournal of the Neurological Sciences · 2025
12. Efficacy and Safety of Nipocalimab in Adults With Generalised Myasthenia Gravis: An Asian Subgroup Analysis of the Vivacity-MG3 StudyJournal of Clinical Neurology · 2026
13. Establishment of an electronic library in forensic psychiatric wards: a survey of its actual use by forensic inpatientsBMC Psychiatry · 2025
14. Measuring the effect of rozanolixizumab using the Myasthenia Gravis Impairment Index: analyses from the randomized phase 3 MycarinG studyJournal of Neurology · 2025
15. Improvement in Patient‐Reported Symptoms of Generalised Myasthenia Gravis With Rozanolixizumab in the Randomised Phase 3 MycarinG Study Using the MG Symptoms PROEuropean Journal of Neurology · 2025
16. Predicting achievement of clinical goals using machine learning in myasthenia gravis.2025
17. Long-term Efficacy and Safety of Amifampridine Phosphate (Firdapse®) in Japanese Patients with Lambert-Eaton Myasthenic Syndrome (LMS-005 Study)Internal Medicine · 2025
18. Changes in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravisJournal of Neurology · 2025
19. Association between Myasthenia Gravis and SmokingInternal Medicine · 2025
20. Fine-scale population structure of Japanese Helicobacter pylori provides new anthropological and epidemiological insightsMicrobial Genomics · 2025